Targeting castration-resistant prostate cancer with a novel RORγ antagonist elaiophylin

Prostate cancer (PCa) patients who progress to metastatic castration-resistant PCa (mCRPC) mostly have poor outcomes due to the lack of effective therapies. Our recent study established the orphan nuclear receptor RORγ as a novel therapeutic target for CRPC. Here, we reveal that elaiophylin (Elai),...

Descripción completa

Detalles Bibliográficos
Autores principales: Zheng, Jianwei, Wang, Junfeng, Wang, Qian, Zou, Hongye, Wang, Hong, Zhang, Zhenhua, Chen, Jianghe, Wang, Qianqian, Wang, Panxia, Zhao, Yueshan, Lu, Jing, Zhang, Xiaolei, Xiang, Songtao, Wang, Haibin, Lei, Jinping, Chen, Hong-Wu, Liu, Peiqing, Liu, Yonghong, Han, Fanghai, Wang, Junjian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7745055/
https://www.ncbi.nlm.nih.gov/pubmed/33354503
http://dx.doi.org/10.1016/j.apsb.2020.07.001

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7745055/
https://www.ncbi.nlm.nih.gov/pubmed/33354503
http://dx.doi.org/10.1016/j.apsb.2020.07.001

Ejemplares similares